At least five states with medical marijuana programs have shared key data – including the products patients are using and how they are affected – with U.S. health regulators as part of the Biden administration’s review of whether to remove marijuana from the federal government’s list of the most dangerous drugs, MJBizDaily has learned.
The state data sent to the U.S. Food and Drug Administration and the Department of Health and Human Services (HHS) offers federal researchers a wider and deeper look into marijuana use and its medical potential than most peer-reviewed studies available to researchers, experts told MJBizDaily.
ADVERTISEMENT
In sharing the data, officials hope to influence the ongoing federal review of cannabis’ status under the Controlled Substances Act (CSA), which still serves as an immovable barrier to long-awaited federal marijuana reform, including interstate commerce and tax relief.
President Joe Biden ordered the review last fall.
Read full article on Marijuana Business Daily
